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ABSTRACT
Sepsis accounts for more than 50% of hospital deaths, and the associated cost ranks the highest among hospital admissions
in the US. Improved understanding of disease states, severity, and clinical markers has the potential to significantly improve
patient outcomes and reduce cost. We develop a computational framework that identifies disease states in sepsis using clinical
variables and samples in the MIMIC-III database. We identify six distinct patient states in sepsis, each associated with different
manifestations of organ dysfunction. We find that patients in different sepsis states are statistically significantly composed of
distinct populations with disparate demographic and comorbidity profiles. Collectively, our framework provides a holistic view of
sepsis, and our findings provide the basis for future development of clinical trials and therapeutic strategies for sepsis.
1 Introduction
Sepsis accounts for more than 50% of hospital deaths26, and the cost of sepsis management ranks the highest among hospital
admissions for all illnesses in the United States31. Key factors in improving patients’ outcomes are the early diagnosis of sepsis,
and subsequent timely and appropriate treatment actions. While significant progress has been made towards the former45, 47,
with recent development of the Sequential Organ Failure Assessment (SOFA or Quick-SOFA) measure outside the Intensive
Care Unit (ICU)22–25, the latter continues to be a significant challenge14, 15, 18, 19, 33, 36. There have been a number of efforts
aimed at classifying disorders that broadly comprise sepsis, which have resulted in categories such as Systemic Inflammatory
Response Syndrome (SIRS), severe sepsis, and septic shock. These, in turn, have resulted in treatment strategies with limited
success. More recently, these categorizations have been abandoned, in favor of a more broadly accepted definition of sepsis as a
‘life-threatening organ dysfunction caused by a dysregulated host response to infection’1. This dysfunction is characterized by a
SOFA score of two points or more. Although SOFA score is a more comprehensive measure of the severity of health status of
ar
X
iv
:2
00
9.
10
82
0v
1 
 [q
-b
io.
QM
]  2
1 S
ep
 20
20
patients with sepsis, and a good predictor of mortality121–123, the diverse mechanisms underlying sepsis and how they map to
SOFA scores are still not fully understood. This is in spite of significant efforts aimed at developing and deploying new and
improved treatments. As a result, current approaches to sepsis treatment are primarily guideline-based, as opposed to relying on
clinicians’ decision-making capability, when presented with a patient’s unique set of clinical variables19.
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Figure 4. Primary function expressions for each sepsis state.
the expression level of its corresponding biomarkers weighted by the confidence level. Specifically, for each primary function,
we firstly calculate how far is the expression of the biomarker is from the boundary of the normal range for each sepsis state,
called di, where i denotes the sepsis state i. We then normalize each di by dividing the maximum of the distance across sepsis
states, i.e., di/max{d1, . . . ,dK}. Since each primary function has multiple biomarkers, we could calculate the final expression
of the primary function as a summation of the di/max{d1, . . . ,dK} for each biomarker. However, each biomarker has different
confidence level with the lesser the confidence level the less trustworthy it is in calculating the final expression of the primary
function. Therefore, we define the final expression of the primary function as a summation of the di/max{d1, . . . ,dK} for each
biomarker weighted by its corresponding confidence level. We then normalize the final value into the range from 0 to 10. If the
value is close to 10, it indicates a higher expression of the primary function, and vice versa. The result for each sepsis state is
shown in Figure 4. In what follows, we also provide a detailed examination of the expression level of the biomarkers for each
primary function. For convenience, we give give a summary of which biomarkers belong to which primary function in Table 2.
Nervous System function : GCS is the most commonly used method of bedside assessment of brain injury and later it is
also used for assessing the consciousness level of critically ill patients, such as sepsis patients.20, 21. GCS estimates coma
severity based on eye , verbal , and motor criteria. It classifies the person into mild (score = 13 – 15), moderate (score = 9 – 12),
severe (score = 3 – 8), and vegetative state (score less than 3)22.
The mean value of GCS score in A1, A2, A3, A4, A5, and A6 states are 12.56, 12.24, 13.96, 10.67, 11.20, and 11.77
respectively. Thus, the non-MODS group is within the range of mild state whereas the MODS group is within the range of
moderate state. Among all sepsis states, A3 state exhibits the highest consciousness level while A4 sate exhibits the lowest
consciousness. The ranking order of the sepsis states for the mean value of GCS score is A4 > A5 > A6 > A1 > A2 > A3, which
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Figure 5. (a) The population distribution for each sepsis state stratified by age. (b) The population distribution for each
sepsis state stratified by weight. (c) The population distribution for each sepsis state stratified by premorbid count. (d)
shown in Figure 5a.
We find that while the average age in the A1, A3, and the A4 states are close to the average age in this cohort the average
age in the A2, A5, and the A6 states are significantly lower than the the average age. In this cohort, the average age is 64.57
years and the average age in the A1, A2, A3, A4, A5, and theA6 states are 64.66 years, 56.57 years, 64.85 years, 62.77 years,
51.57 years, and 54.28 years respectively. Note that while the age is not an independent parameter of the health outcomes, we
find that the trend of increasing a worse outcome in elder people for severe sepsis states. In the MODS group, we notice that
the A4 state that was shown to be associated with the highest mortality is also has the highest average age. In the non-MODS
group, on the other hand, we find that the sepsis state that exhibits notable expression of inflammatory response, namely the A2
state, is associated with a lower age.
The distribution for each the sepsis state stratified by weight are shown in Figure 5b. We find that the difference of the
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Figure 1: Illustration of proposed framework: The data preparation phase extracts 42 variables (demographic profiles, vital
signs, laboratory tests, mechanical ventilation status of the patients, and the comorbidity profiles) from 16,546 distinct sepsis
patients admitted to Beth Israel Deaconess Medical Center from the MIMIC-III d tabas . In t e data analysis phase, we
use archetypal analysis to find distinct states of sepsis. We then us dimen on reducti n method (UMAP) to visualize the
identified sepsis states. For analyzing each state, a statistical test (MANOVA) is performed to validate that the clusters are
significantly different from the distribution of the cohort as a whole, and the SOFA score, SIRS score, and mortality rate
are calculated to characterize each sepsis state. In primary function analysis, selected features from archetypes are used to
identify the primary functions (namely, nervous system, inflammation and infection, liver function, kidney function, coagulation,
respiratory function, and, cardiovascular function) of each sepsis state. Finally, in etiological analysis, we perform z-score
analysis to find correlation between pre-existing comorbidity profiles (30 types) and sepsis states.
A personalized decision process for sepsis must be capable of differentiating heterogeneous response from diverse groups
of patients, and understanding the etiology of disease to minimize errors and maximize treatment efficacy. With the goal
of motivating research on such personalized decision processes, the Medical Information Mart for Intensive Care version
III (MIMIC-III)51 database released de-identified clinical data from approximately 46,000 patients admitted to Beth Israel
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Deaconess Medical Center in Boston, Massachusetts between 2001 and 2012. We use clinical variables in the MIMIC-III
database, along with a range of novel algorithmic and statistical constructs for our retrospective study of sepsis states and
response (Figure 1).
We first identify a patient cohort that satisfies the sepsis-3 criteria1 from five tertiary ICUs in Boston. This results in a
sample of 16,546 distinct patients with 20,944 ICU admissions. We then extract clinical variables for the cohort, including
demographic data, vital signs, lab results, and other information such as the use of a ventilator, and the number of comorbidities
before sepsis infection, to characterize the health status of the patients with sepsis during the ICU stay. We summarize this
data in Table 1. We develop a mathematical framework that: (i) identifies distinct sepsis states using archetypal analysis; (ii)
extracts significant sets of features from clinical variables to differentiate sepsis states and identifies associated biomarkers that
can be mapped back to organ function(s); and (iii) analyzes relationships between sepsis states, demographic variables, and
comorbidities before infection.
We demonstrate that our framework uncovers distinct sepsis states – each state characterized by a unique set of pathological
responses that can be mapped back to organ function(s), and an association between patient attributes and sepsis states. Our
framework provides a holistic view of the diverse set of conditions that comprise sepsis. Our analysis reveals six sepsis states
– among these states, State 1 manifests a mild condition of sepsis, State 2 primarily represents inflammation and infection
with evident signs of inflammatory responses, State 3 corresponds to the highest survival rate, but is typically associated with
hyperoxia. The last three states show signs and symptoms of Multiple Organ Dysfunction Syndrome (MODS) with diverse
manifestations of organ failures. We also find that patients with sepsis being categorized into these states manifest distinct
demographic profiles. Patients categorized as inflammation type or the second and third MODS type are at least eight years
younger than the average for the cohort; patients with the second type of MODS tend to be overweight, and the average weight
of patients in the third type is 3.99 kilograms lower than the average cohort weight of 83.27 kilograms. Finally, these states also
manifest distinct comorbidities profiles before infection. Patients with weight loss, alcohol abuse, or paralysis are more likely
to develop the inflammation type, patients with coagulopathy and liver disease are more likely to develop MODS types, patients
in the first MODS type are associated with solid tumors. Patients in the second MODS type are associated with depression
and other related conditions, such as drug and alcohol abuse, obesity, and peptic ulcer disease. Patients in the third MODS
type are associated with valvular disease, pulmonary circulation, other neurological disorders, and rheumatoid arthritis. These
results provide a better understanding of the etiology and pathological process of sepsis, and guides design of clinical trials and
therapeutic strategies for future investigations. 1
1This is a retrospective study. Future studies that involve AI intervention or treatment guidelines would be in compliance with guidelines for AI clinical
research50.
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Table 1: Description of the cohort.
Demographic Type or Unit Normal Range Mean (std) Value in Cohort
Age years N/A 64.5738 (16.665)
Gender binary 1 = Female, 0 = Male 0.4396 (0.4963)
Vitals
HR bpm 60 - 100 87.208 (16.8358)
SysBP mmHg ≤ 120 119.9199 (20.3514)
MeanBP mmHg 70 - 100 78.2144 (13.4891)
DiaBP mmHg 80 57.1157 (13.3192)
Temp Celsius 36.5 - 37.5 36.9062 (2.0132)
RR bpm 12 - 20 20.2073 (5.1868)
Lab Values
GCS N/A 15 12.5734 (3.4482)
SpO2 percent 95 - 100 96.9085 (2.6548)
FiO2 fraction .21% inhaled from natural air 0.4604 (0.1834)
Potassium mEq/L 3.5 - 5.0 4.0789 (0.5594)
Sodium mEq/L 135 - 145 138.6876 (4.8859)
Chloride mEq/L 96 - 106 104.7204 (6.2447)
Glucose mg/dL 80 - 130 138.9572 (51.1809)
BUN mg/dL 7 - 20 29.2462 (22.5642)
Creatinine mg/dL 0.6 (0.5) -1.2 (1.1) males (females) 1.4886 (2.1624)
Magnesium mg/dL 1.5 - 2.5 2.055 (0.3521)
Calcium mg/dL 8.8 - 10.7 8.3136 (0.7982)
Ionised Ca mmol/L 1.16 - 1.32 1.1315 (0.1219)
CO2 mEq/L 23 - 29 25.822 (5.6583)
SGOT u/L 5 - 40 155.6854 (583.5742)
SGPT u/L 7 - 56 583.5742 (466.3519)
Total Bilirubin mg/dL 0.1 - 1.2 2.4121 (5.1454)
Albumin g/dL 3.4 - 5.4 3.0015 (0.6761)
Hb g/dL 13.5 (12.0) - 17.5 (15.5) males (females) 10.3012 (1.7361)
WBC × 109 /L 4.5 - 11.0 12.2717 (8.2931)
Platelets × 109 /L 150 - 450 228.6988 (139.1926)
aPTT s 30 - 40 37.8122 (19.3446)
PT s 11 - 13.5 16.1932 (6.754)
INR N/A ≤ 1.1 1.5122 (0.836)
Arterial PH N/A 7.35 - 7.45 7.3904 (0.0743)
PaO2 mmHg 80-100 125.1477 (72.4518)
PaCO2 mmHg 35-45 41.9454 (10.8051)
Arterial BE mEq/L -2 - +2 0.3483 (5.0234)
Arterial lactate mmol/L 0.5-1 2.0541 (1.6579)
HCO3 mEq/L 22 - 28 24.6717 (5.0855)
Shock Index bpm/mmHg 0.5 - 0.7 0.7484 (0.1964)
PaO2/FiO2 mmHg > 500 at sea level 310.9979 (223.7143)
Others
Weight kg N/A 83.2268 (24.6507)
Mechvent binary 0 = False, 1 = True 0.3689 (0.4825)
Comorbidity Count Integer 0 - 30 4.0059 (2.1703)
All of the normal ranges presented apply to adults. HR, Heart Rate; SysBP, Systolic Blood Pressure; MeanBP, Mean Blood Pressure; DiaBP, Diastolic
Blood Pressure; Temp, Temperature; GCS, Glasgow Coma Scale; RR, Respiratory Rate; BUN, Blood Urea Nitrogen; SGOT, Serum Glutamic-Oxaloacetic
Transaminase; SGPT, Serum Glutamic Pyruvic Transaminase; Hb, Hemoglobin; WBC, White Blood Cells; PTT, Partial Thromboplastin Time; PT, Prothrombin
Time; INR, International Normalized Ratio, Arterial BE, Arterial Base Excess.
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2 Results
2.1 Identifying distinct sepsis states from the cohort.
2.1.1 Archetypal analysis of sepsis cohort.
We pose the following important question: do there exist distinct states of sepsis with different clinical manifestations,
recovery rates, demographic and pathological characteristics, and is it possible to identify these states from patient clinical
measurements? We formulate this problem as one of finding archetypes (representatives of states) of sepsis, and develop
powerful algorithms for solving this problem. A geometric interpretation of our approach is to view each patient as a point
in a high dimensional space of attributes, and archetypes as corners of a convex hull in this high dimensional space. Within
this representation, each data point can be approximated as a linear combination of the archetypes. Since archetypes form
a convex polytope, the coefficients in the linear combinations sum to one (convex combinations). To account for noise, the
problem of finding archetypes is relaxed from an exact convex hull problem, to one of finding an approximate convex hull
with a given number of corners (archetypes). Mathematically, this is formulated as a constrained optimization problem that
minimizes the squared error in representation of each data point as a linear mixture of archetypes. The optimal number of
archetypes is determined by checking the reduction in the residual (of representations of all data points) and finding the point at
which this residual drops significantly. This formulation has several advantages over traditional clustering techniques (e.g.,
k-means). Archetypes represent extremal or pure states – to this end, they have clear clinical interpretations. Second, each
convex combination has a well-characterized interpretation as a mixture of pure states, thus avoiding negative coefficients (with
associated loss of interpretability) in other methods. Finally, descriptors of archetypes may themselves be processed to identify
clinical markers for the pure states. Using this procedure, we discover six distinct states in sepsis among our cohort.
2.1.2 Testing statistical significance of states.
We characterize the statistical significance of each sepsis state based on the data points (patient records) mapped to the
corresponding archetype from the cohort. Since archetypes represent extreme sepsis states, in the rest of this discussion, we use
the terms “sepsis state" and “archetype" interchangeably. Each point is a mixture of sepsis states and we can assign the point
to the closest sepsis state (the corresponding archetype). A statistical interpretation of this formulation views data points as
mixtures of samples from the six distinct multivariate distributions. To ascertain that these distributions are indeed distinct, we
apply a statistical test, coupled with a dimension reduction technique to the data points. Specifically, we first validate that the
probability distributions corresponding to these groups are significantly different from the distribution of the cohort as a whole.
We also test to ensure that the probability distribution of each group is significantly different from others, as characterized
by a multivariate analysis of variance (MANOVA) procedure. Two-sample testing is sensitive to homogeneity of covariance
matrices from the compared populations. We use the Box test130 to compare variation in multivariate samples. We then use a
Hotelling T-Squared testing variant129 to compare the mean vectors from two populations. We note that covariance matrices
and mean vectors from the compared pairs are significantly different, with a 95 % confidence interval.
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Figure 2 shows a uniform manifold approximation and projection (UMAP) embedding of the data points, along with the
archetypes (represented by colors). Readers may note that archetypes (A1 through A6) do not appear as corners of the convex
polytope, since this is a two-dimensional embedding of a higher dimensional attribute space.
Figure 2: Visualization (using low-dimensional UMAP embedding) of the six derived sepsis states. Colors represent different
sepsis states. Co-occurrence ( See section 4) analysis is used to compute the SOFA score, SIRS score, and mortality rate
of each sepsis state. Based on these scores, we characterize states A1 (blue), A2 (orange), and A3 (green) as ‘moderate
condition’, ‘inflammation’, and ‘mild condition’, respectively, and we characterize states A4 (red), A5 (brown), and A6 (purple)
as ‘Multiple Organ Dysfunction Syndrome (MODS)’.
2.1.3 Characterizing sepsis states : SOFA score, SIRS score, and mortality rate.
We use the SOFA score, SIRS score, and mortality rate as measures to characterize sepsis states. We calculate the average
SOFA score and SIRS score for patients in each state. We also apply co-occurrence analysis (See Methods Section 4 for more
details) to calculate the conditional probability of death, given a sepsis state. The average values of SOFA scores in states A1,
A2, A3, A4, A5, and A6 are 6.34, 5.66, 3.99, 10.06, 8.54, and 7.99, respectively. The average values of SIRS scores in states
A1, A2, A3, A4, A5, and A6 are 1.62, 2.28, 1.39, 1.86, 1.74, and 1.76, respectively.
Based on the SIRS criteria, a patient with SIRS score higher than two is diagnosed with sepsis infection (please see full
discussion in Appendix Section 5.2). This definition of sepsis is mainly focused on signs of inflammation exhibited by patients.
We find that, among the sepsis states, only state A2 satisfied the SIRS criteria. Consequently, we identify state A2 as primarily
representing inflammatory response. According to the sepsis-3 criteria1, sepsis is defined as having a SOFA score higher than
two, and the higher the score is, the more severe the condition is. It is reported that patients who developed Multiple Organ
6/46
Dysfunction Syndrome (MODS) display significantly higher mortality rate8, 14, 16–18. We observe that the mortality rate, as well
as the SOFA scores of state A4, A5, and A6 are significantly higher than the other types. Thus, we hypothesize that the A4, A5,
and A6 represent MODS with heterogeneous organ dysfunction. Compared to the MODS states, states A1 and A3 display
lower mortality rates and SOFA scores, with A3 having the lowest mortality rate and SOFA score. Therefore, we characterize
states A1 and A3 as ‘moderate condition’ and ‘mild condition’, respectively.
A restrictive definition of sepsis has significant adverse implications for diagnosis and treatment. The SIRS metric has been
criticized for its inability to identify all possible host responses for sepsis since the SIRS criteria focuses solely on inflammatory
excess; hence it is an inaccurate predictor for mortality. This diagnostic metric for sepsis was replaced by sepsis-2126, and
eventually by sepsis-3. Sepsis-3 uses the SOFA score to characterize the health status of patients with sepsis. It has been shown
to be a more accurate predictor of mortality116, compared to SIRS and sepsis-2. Our results support the arguments against the
SIRS metric, and reinforce the use of SOFA scores for severity of sepsis infections. As mentioned earlier, only state A2 in our
cohort qualified as a sepsis infection based on SIRS scores – leading to potentially inadequate care for other sepsis states. Our
analysis demonstrates that SOFA scores correlate well with our identified states, and that the severity and mortality rate for
identified states correlates well with their SOFA sores. However, as we show in the rest of this study, SOFA score alone does
not capture the diversity of sepsis states – motivating our multidimensional approach based on archetypal analysis.
2.2 Selecting distinguishing features of sepsis states.
                  
SGOT        SGPT        PT        PaO2                  PaO2 / FiO2
WBC Count     Platelets Count   Arterial Lactate 
  
Comorbidity Count  Creatinine
         Weight   PTT 
DiaBP   Glucose     BUN
  
Age      HR  
GCS   FiO2    Mechvent   INR 
None
Figure 3: Visualization of the selected features (21 features in total) by Q j(PK) , Q′j(PK) , and Variation test. Q j(PK) calculates
the discriminative power of feature i for a given clustering as the ratio of inter-cluster inertia to the total inertia computed using
feature i. Q′j(PK) calculates the discriminative power of feature i as the ratio of inter-cluster inertia computed using feature i to
total inter-cluster inertia computed using all features. Variation test selects features that have the lowest probability of overlap
across clusters (please see Methods section 4 for more details). Note that there is a significant overlap between features chosen
by these selection criteria. However, each criterion yields a distinct set of features significantly associated with different sepsis
states.
In Section 2.1.3, we used the SOFA score, SIRS score, and mortality rate to characterize sepsis states and find that the
SOFA score is a distinguishing feature of our sepsis states. However, SOFA score provides few insights into the subset of
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pathological responses that are uniquely expressed in each sepsis state. This, in turn, reflects the unique expression of organ
functions that differentiate individual states. Specifically, two patients with similar SOFA scores may exhibit disparate signs of
organ dysfunction. It is possible to analyze the SOFA score for each organ system1. However, only a few clinical variables are
used to evaluate the SOFA score, and therefore SOFA scores do not provide accurate measures of the functional state of the
organ system. Once we identify sepsis states and corresponding data points (patient assignment to states), we can identify the
complete set of clinical attributes that uniquely characterize each state; many of these attributes are not included in the SOFA
score computation. This allows us to develop a finer-grained characterization of overall clinical disposition associated with
each sepsis state.
To identify discriminative attributes for each state, we have developed three criteria. The first two criteria are based on
Huygens-Steiner theorem to measure the inertia (i.e., the tendency of a physical object to remain still, or continue in motion)
of the points in Euclidean space. The third criterion finds the most distinct features across populations and prunes them for
each state. The first method, which we refer to as the Q j(PK), calculates the discriminative power of feature i for a given
clustering as the ratio of inter-cluster inertia to the total inertia computed using feature i. Intuitively, this method quantifies
the heterogeneity of feature i across clusters. The second method, which we refer to as Q′j(PK) calculates the discriminative
power of feature i as the ratio of inter-cluster inertia computed using attribute i to total inter-cluster inertia computed using all
attributes. Intuitively, this method computes the relative heterogeneity of feature i with respect to all other features. The third
method uses a variation test that selects features that have the lowest probability of overlapping across clusters (please see
method section 4 for more details). We find that although there is a considerable overlap of selected features between these
methods, there are few features that are uniquely selected by the measures. We rank the features in terms of the number of
criteria that select the particular feature, and extract the top 15 features based on this ranking. As shown in Figure 3, 8 features,
i.e., SGOT, SGPT, PT, PaO2, PaO2/FiO2, WBC Count, Platelets Count, and Arterial lactate, were selected by all three criteria;
6 features, i.e., Age, HR, GCS, FiO2, Mechvent, and INR , were selected by two; and 7 features, i.e., Weight, PTT, DiaBP,
Glucose, BUN, Creatinine and Comorbidity Count were selected by one. We use these features to analyze the primary profiles
for each sepsis state in the next section.
2.3 Analyzing the primary attributes for sepsis states.
Among the 21 features selected by our methods, 18 are the vitals and lab results that are known biomarkers of organ functions,
or of other aspects of overall health. From this set of features, we identify associated primary health indicators, corresponding
to the nervous system, inflammation and infection, liver function, kidney function, coagulation, respiratory function, and
cardiovascular function. We refer to these seven as primary functions. We measure the overall expression of each of these
primary functions for each sepsis state using the level of corresponding biomarkers, weighted by the confidence level. For sepsis
state i, we calculate distance di between readings from the biomarkers to the boundary of the normal range for each primary
function. We then normalize each di by dividing by the maximum of the distance across sepsis states, i.e., di/max{d1, . . . ,dK}.
Since each primary function can be tested by more than one biomarker, each of which has a different confidence level, we define
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the final expression of the primary function as a summation of normalized distance. The final value is linearly normalized into
the range from 0 to 10, with higher values indicating higher expression of the primary function. The spider-plot of primary
functions affected in each sepsis states is shown in Figure 4.
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Figure 4: Spider-plot of primary functions affected in each sepsis state (represented by corresponding colors). There are seven
different dimensions of primary function for each sepsis sate. The measured dimensions are nervous system, inflammation and
infection, liver function, kidney function, coagulation, respiratory function, and cardiovascular function, respectively. The scale
of each dimension ranges from 0 to 10, with higher values indicating higher affect on the primary function.
We find that each sepsis state manifests distinct expressions of organ dysfunction. We provide a detailed examination of the
expression level of the biomarkers for each primary function next. We provide: (i) the biomarkers that are used in assessment
of organ function; (ii) the severity level of biomarkers to assess organ function, and (iii) the expressions of these biomarkers in
each sepsis state.
2.3.1 Nervous System.
We use the Glasgow Coma Scale (GCS) to evaluate the state of the nervous system. GCS is commonly used for bedside
assessment of brain injury, and for assessing the consciousness level of critically ill patients, including those with sepsis150, 151.
GCS estimates coma severity based on eye, verbal, and motor criteria, and classifies the patient into mild (score = 13 – 15),
moderate (score = 9 – 12), severe (score = 3 – 8), and vegetative state (score less than 3)152. We find that the average GCS scores
for states A1 through A6 are 12.56, 12.24, 13.96, 10.67, 11.20, and 11.77, respectively. This indicates that the non-MODS
states – A1, A2, and A3, are mild GCS states, while the MODS states – A4, A5, and A6 states, are within the range of moderate
GCS state. Among all of the sepsis states, state A3 displays the highest level of consciousness, while the A4 corresponds to
the lowest level of consciousness. The order of the GCS scores, SOFA scores, as well as mortality rate of sepsis states, are
identical, indicating that the GCS score is a good predictor of mortality for patients with sepsis, and that our method identifies
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sepsis states consistent with the GCS assessment.
2.3.2 Inflammation and Infection.
White Blood Cell (WBC) count, Heart Rate (HR), and platelet count are used to evaluate inflammation and infection response
in the body. Among these, WBC count and HR are also used in the SIRS criteria to characterize systemic inflammation117. In
acute inflammatory conditions, an increase in HR is often observed168–170. HR in sepsis increased when patients suffer from
hypovolemia and hypoperfusion. The WBC count increases from a normal value of 4.5 to 11.0 × 109 /L to 15.0 to 20.0 × 109
/L165, with WBC levels higher than 11.0 defined as leukocytosis166. While not considered in the SIRS criteria, the elevation
of platelet count is an important indicator for inflammation and infection171–176. Inflammatory conditions such as bacterial
infection, sepsis, malignancy, and tissue damage, motivate a reactive response that elevates platelet count, namely secondary
thrombocytosis (platelet count higher than 500 × 109 /L)21.
We find that leukocytosis and secondary thrombocytosis are observed in state A2. This state displays the highest average
WBC count, platelet count, and HR with an average of 20.70 × 109 /L, 905.58 × 109 /L, and 95.57, respectively. The average
WBC count in state A3 is within, but close to the maximum of the normal range (10.95 × 109 /L). Slightly elevated WBC count
is observed in states A1, A4, A5, and A6, with an average of 12.22 × 109 /L, 13.12 × 109 /L, 11.24 × 109 /L, and 13.01 × 109
/L, respectively. The average platelet counts in states A1, A3, A4, A5, and A6 are within the normal range, with averages of
223.79 × 109 /L, 229.67 × 109 /L, 185.09 × 109 /L, 189.93 × 109 /L, and 194.64 × 109 /L, respectively.
In summary, states A1, A3, A4, A5, and A6 show few signs of inflammation. In contrast, state A2 reveals high inflammatory
response, as all the inflammatory biomarkers – WBC count, platelet count, and HR, are significantly elevated.
2.3.3 Liver function.
SGOT, SGPT, and arterial lactate are used to characterize liver function. An increase in SGOT and SGPT levels indicates
damage to the liver141. In general, the severity of liver dysfunction can be classified as mild, moderate, or severe if elevation of
SGOT and SGPT levels is less than 5 times, 5-10 times, and 10-50 times the upper reference limit. In addition to SGOT and
SGPT, arterial lactate is a biomarker for liver dysfunction182. Arterial lactate is primarily cleared by the liver, with a small
amount of additional clearance by the kidneys144. Thus, arterial lactate is elevated when liver function is compromised144. In a
healthy body, the lactate level is usually less than two mmol/L. Patients with hyperlactatemia usually have lactate levels higher
than two mmol/L. Lactate levels higher than four mmol/L are considered to be in a severe state of hyperlactatemia20.
We find that non-MODS states – A1, A2, and A3, reveal mild liver damage, with only a mild increase in SGOT and SGPT
levels (less than 5 times the upper reference limit141), as well as a mild increase in arterial lactate. The average SGOT levels in
states A1, A2, and A3 are 121.20 u/L, 115.25 u/L, and 97.13 u/L, respectively; the average levels of SGPT in states A1, A2,
and A3 are 104.71 u/L, 103.37 u/L, and 81.68 u/L, respectively; and the average arterial lactate levels in states A1, A2, and A3
are 2.04 mmol/L, 1.88 mmol/L, and 2.10 mmol/L, respectively. In contrast to non-MODS states, SGOT, SGPT, and arterial
lactate are all in severe levels in MODS states – A4, A5, and A6. The average SGOT levels in states A4, A5, and A6 are 6.56 ×
103 u/L, 2.01 × 103 u/L, and 7.66 × 103 u/L, respectively; the average SGPT levels in states A4, A5, and A6 are 3.02 × 103
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u/L, 6.39 × 103 u/L, and 6.69 × 103 u/L, respectively; and the average arterial lactate levels in states A4, A5, and A6 are 5.50
mmol/L, 3.95 mmol/L, and 4.59 mmol/L, respectively. Not identified by our feature selection methods, but also a representative
biomarker, high levels of bilirubin are often associated with liver damage189. Patients with sepsis having (i) bilirubin ≥ 4.0
mg/dL, or (ii) SGPT levels of twice the upper limit of normal for age are considered to have a sepsis-associated liver injury
(SALI)190. A high level of bilirubin ( ≥ 2.5 to 3 mg/dL) can cause jaundice. The development of jaundice may occur due to
issues with processing of bilirubin by hepatocytes, or from other effects on the liver that lead to the accumulation of bilirubin
in the body. Such processes include increased bilirubin load from hemolysis, hepatocellular injury, and cholestasis, from the
septic state, and from drugs used for the treatment of sepsis191. In our study, the average bilirubin levels in states A4, A5, and
A6 are 5.37 mg/dL, 3.37 mg/dL, and 4.56 mg/dL, respectively, indicating common occurrence of jaundice in MODS states.
In summary, non-MODS states reveal mild liver damage, reflected in a mild increase in SGOT, SGPT, and arterial lactate
levels. In contrast, MODS states display severe liver dysfunction, with SGOT, SGPT, and arterial lactate all at severe levels.
This is generally accompanied with jaundice. Finally, we note that state A6 potentially develops ischemic injury, since we
observe that: (i) both SGOT and SGPT are more than 50 times higher than the upper reference limit; and (ii) SGOT is greater
than SGPT141. We show in the next section that the development of ischemic injury is related to a set of comorbidities associated
with state A6 before sepsis infection.
2.3.4 Kidney function.
Blood Urea Nitrogen (BUN) test and serum creatinine, identified by our feature selection methods, are common biomarkers of
Acute Kidney Injury (AKI)145, 146, 181. AKI180, defined as a sudden episode of kidney failure or kidney damage that happens
within a few hours or a few days, is a common complication in sepsis patients. It is associated with high morbidity and
mortality179. BUN measures the amount of urea nitrogen in the blood. Urea nitrogen is removed from the blood by the kidneys;
consequently, high BUN levels indicate potential kidney damage. A serum creatinine test provides an estimate of filtration
efficiency of kidneys (glomerular filtration rate). An increased level of creatinine in blood is indicative of potential impaired
kidney function.
We find that state A3 exhibits relatively better kidney function when compared to the other sepsis states since both serum
creatinine (1.02 mg/L) and BUN (24.96 mg/L), though slightly elevated, are the lowest. In the rest of the states, damage to
kidneys is observed, with state A4 being the worst. The average levels of serum creatinine in states A1, A2, A4, A5, and A6 are
1.489 mg/L, 1.450 mg/L, 2.05 mg/L, 2.0 mg/L, and 2.0 mg/L, respectively; and the BUN levels in states A1, A2, A4, A5, and
A6 are 29.31 mg/L, 26.68 mg/L, 33.63 mg/L, 26.26 mg/L, and 29.35 mg/L, respectively.
2.3.5 Coagulation function.
Activated Partial Thromboplastin Time (aPTT), Prothrombin Time (PT), and International Normalized Ratio (INR) are identified
by our feature selection methods. These are measures of coagulation function. Sepsis-associated coagulopathy (SAC) is
typically diagnosed by PT prolongation or elevated INR, in conjunction with reduced platelet count147. aPTT is also used as a
test for coagulation in patients with sepsis148, 149. Increased aPTT and PT above normal values, and decreased platelet count
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below normal value indicate long clotting time (DIC) and bleeding in sepsis patients188.
We find that in non-MODS states, aPTT is within the normal range, and that INR and PT are slightly elevated. The average
aPTT values in states A1, A2, and A3 are 37.78 s, 37.52 s, and 37.84 s, respectively; the average INR values in states A1, A2,
and A3 are 1.51, 1.46, and 1.48, respectively; and the average PT values in states A1, A2, and A3 are 16.16 s, 15.91 s, and
15.88s, respectively. In contrast to non-MODS states, an increase in values of INR, PT, and aPTT is observed in MODS states.
The average aPTT values in states A4, A5, and A6 are 44.14 s, 41.61 s, and 43.14 s, respectively; the average INR values in
states A4, A5, and A6 are 2.08, 2.49, and 2.96, respectively; and the PT values in states A4, A5, and A6 are 20.68 s, 21.92 s,
and 25.93 s, respectively. We also examine the platelet count in these states. Although the average platelet count in all sepsis
states is within the normal range, a higher percentage of the cases with a platelet count below the normal range (150 × 109 /L)
are observed in MODS states. The percentage of cases with platelet count lower than normal from states A1 to A6 are 30%,
0%, 27.7%, 44.9%, 40.3%, and 44.9%, respectively.
In summary, nearly one-third of the cases in states A1 and A3 develop a mild condition of SAC or DIC, while more than
40% of cases in the MODS group have worse SAC or DIC.
2.3.6 Respiratory function.
Partial pressure of oxygen (PaO2), fraction of inspired oxygen (FiO2), ratio of the arterial partial pressure of oxygen to fraction
of inspired oxygen (PaO2/FiO2), and the indication of the patient being assisted by mechanical ventilator, are identified by
our feature selection methods. These are commonly used to measure respiratory function. Partial pressure of oxygen (PaO2)
measures the pressure of oxygen dissolved in blood, and how well oxygen can move from the airspace of the lungs into
the blood. The fraction of inspired oxygen (FiO2) is defined as the concentration of oxygen that a person inhales. Patients
experiencing difficulty in breathing are provided with oxygen-enriched air161. Therefore, higher FiO2 is observed if the
respiratory function is compromised. The ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2)
is a known measure for the assessment of respiratory dysfunction158, such as Acute Respiratory Distress Syndrome (ARDS)140.
Under the Berlin ARDS definition160, patients with PaO2/FiO2 levels in the range of 200–300, 100–200, and less than 100 are
classified as mild, moderate, and severe ARDS. The SOFA metric also incorporates PaO2/FiO2 as a parameter in assessing
respiratory function1. According to the SOFA score, a normal person has a PaO2/FiO2 ratio of approximately 500 and a patient
with PaO2/FiO2 ratio between 300 – 400, 200 – 300, 100 – 200, and less than 100 would have SOFA scores 1, 2, 3, and 4,
respectively. Thus, a lower PaO2/FiO2 ratio indicates worse respiratory condition. Conversely, high PaO2/FiO2 ratio (PaO2 >
300 mmHg) indicates that the lung is exposed to hyperoxia162. Mechanical ventilators155, 156 are often used in ICUs to assist or
replace spontaneous breathing, indicating compromised respiratory function.
We find that patients in state A3 display excessive amounts of PaO2 and a slight increase in FiO2 (0.07 higher than the
normal value of 0.21, on average). This indicates that patients in state A3 are less prone to lung dysfunction, but that state A3
manifests hyperoxia. The lower fraction of patients on ventilators in state A3 also indicates better lung function, compared to
other states. The fraction of patients on a ventilator in state A3 is the lowest, at 0.09. The FiO2/PaO2 parameter also indicates
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that state A3 does not develop ARDS. Distinct from state A3, respiratory functions are compromised to varying extents in other
states. We find that both PaO2 and FiO2 in states A1, A2, A4, A5, and A6 are slightly elevated. The average values of PaO2 in
states A1, A2, A4, A5, and A6 are 20.83 mmHg, 21.77 mmHg, 26.95 mmHg, 20.98 mmHg, and 17.92 mmHg, respectively,
and the average values of FiO2 in states A1, A2, A4, A5, and A6 are 0.46, 0.47, 0.52, 0.48, and 0.47, respectively. A higher rate
of patients on ventilators is observed in states A1, A2, A4, A5, and A6, with the mean value of 0.37, 0.33 0.56, 0.50, and 0.41,
respectively. We observe that states A1, A2, A4, A5, and A6 correspond to mild ARDS. The average values of FiO2/PaO2 in
states A1, A2, A4, A5, and A6 are, respectively, 292.98 mmHg, 294.59 mmHg, 285.03 mmHg, 318.13 mmHg, and 301.8 5
mmHg, which is close to the boundary of normal value of 300mmHg in the Berlin ARDS definition and close to SOFA score of
2. We highlight that among these states, state A4, one of the MODS states that displays the highest SOFA score and mortality
rate, shows the highest FiO2, the lowest PaO2/FiO2, and the highest rate of ventilator use.
In summary, states A1, A2, A4, A5, and A6 manifest mild respiratory dysfunction with state A4 being the worst. State A3
shows better respiratory function, as the average value of FiO2, and rate of ventilator use is the lowest. According to both the
Berlin ARDS definition and SOFA score, state A3 type does not manifest ARDS. However, state A3 manifests hyperoxia, since
the average value of PaO2 in state A3 is higher than 300 mmHg.
2.3.7 Cardiovascular function.
DiaBP, identified by our feature selection method, is a measure of potential hypotension154 and vasopressor use, and can be
used to identify potential septic shock47. Hypotension is generally defined as a systolic blood pressure of less than 90 mmHg
or diastolic of less than 60 mm Hg. Severe hypotension can deprive the brain and other vital organs of oxygen and nutrients,
leading to a life-threatening condition called shock. Patients with septic shock can be identified with a clinical construct of
sepsis with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) of 65 mmHg, and having a
serum lactate level higher than two mmol/L despite adequate volume resuscitation47.
We observe that all sepsis states except A5 show lower blood pressure. The average DiaBP of state A5 is 60.46, and the
average values of DiaBP in states A1, A2, A3, A4, and A6 are 57.07, 59.55, 58.31, 58.07, and 57.00, respectively. We also
find that the dosage of vasopressin in MODS states is significantly higher than non-MODS states. The average dosage of
vasopressin in states A1, A2, and A3 are 0.06 mcg/kg/min, 0.08 mcg/kg/min, and 0.01 mcg/kg/min, respectively. In contrast,
the average dosage of vasopressin in states A4, A5, and A6 are 0.26 mcg/kg/min, 0.13 mcg/kg/min, and 0.13 mcg/kg/min,
respectively.
In summary, non-MODS states show mild hypotension, while MODS states are potentially in septic shock, with state A4
being the worst. It has been shown that the development of septic shock is an accurate predictor of mortality183, 185. Our results
are consistent with these studies, since the severity of the septic shock in states A4, A5, and A6 is consistent with the mortality
rate – the severity level of the septic shock in states A4, A5, and A6 ranked the highest, second, and third, respectively, which is
the same order as the mortality rate.
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Correlation of demographic variables and comorbidities with sepsis states.
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Figure 5: (a) The population distribution for each sepsis type stratified by age. (b) The population distribution for each sepsis
type stratified by weight. (c) The population distribution for each sepsis type stratified by the number of comorbidities before
infection. (d) Z-score analysis of the comorbidity profiles (row) of each sepsis type (column). Entries approaching red in
intensity indicate that the comorbidity profiles are expressed in the corresponding sepsis states, and entries closer to blue
indicate that the comorbidity profiles are suppressed in corresponding sepsis states.
Correlation of demographic variables and comorbidities with sepsis states.
Variations in patients’ demographics, such as gender, age, and medical comorbidities, present additional considerations for
classifying sepsis states9. Our feature selection methods identify age, weight, and comorbidities, indicating that these attributes
are strongly correlated with sepsis states.
2.3.8 Correlation of demographic variables with sepsis states.
The distributions of sepsis states in terms of patient age are shown in Figure 5a. We observe that while the average ages of
patient in states A1, A3, and A4 are close to the average age of the entire cohort, the average age patients in states A2, A5,
and A6 are significantly lower than the average age of the entire cohort – the average age of the entire cohort is 64.57 years,
and the average ages of states A1 to A6 are 64.66 years, 56.57 years, 64.85 years, 62.77 years, 51.57 years, and 54.28 years,
respectively. Several studies have been shown that advanced age has been associated with worse outcomes70,71. We also find
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The distributions of sepsis states in terms of patient age are shown in Figure 5a. We observe that while the average ages of
patient in states A1, A3, and A4 are close to the average age of the entire cohort, the average age patients in states A2, A5,
and A6 are significantly lower than the average age of the entire cohort – the average age of the entire cohort is 64.57 years,
and the average ages of states A1 to A6 are 64.66 years, 56.57 years, 64.85 years, 62.77 years, 51.57 years, and 54.28 years,
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respectively. Several studies have been shown that advanced age has been associated with worse outcomes184, 187. We also find
that worse outcomes are observed in older people for severe sepsis types. Specifically, in MODS states, we observe that state
A4, shown to be associated with the highest mortality, also has the highest average age. On the other hand, we observe that the
sepsis state that demonstrates notable expression of inflammatory response, i.e., A2, is associated with lower average age.
The distributions of sepsis states in terms of patient weight are shown in Figure 5b.We observe that the average weight of
the entire cohort and the average weight of all sepsis states except A5 are within 4 percent. The average weight of patients
in state A5 is 7 percent higher than the average weight of the entire cohort. The average weight of the entire cohort is 83.27
kilograms and the average weight of patients in states A1 to A6 is 83.29 kilograms, 84.95 kilograms, 79.28 kilograms, 85.18
kilograms, 89.30 kilograms, and 82.31 kilograms, respectively.
2.3.9 Comorbidity profiles and their association with sepsis states.
We investigate the association of different comorbidity profiles with sepsis states. First, we construct distributions of sepsis
states by the total number of pre-existing comorbidities, shown in Figure 5c. We observe that, compared to non-MODS states,
the MODS group has a higher number of comorbidities – the average comorbidity count for states A1 to A6 is 4.02, 3.08, 3.65,
4.62, 4.29, and 4.28, respectively. The higher the number of comorbidities, the worse the outcomes of sepsis.
Our results show clear association between comorbidities and patient outcomes. We next analyze the relationship between
specific comorbidity profiles and their association (positive or negative) with sepsis states. We use z-score as a measure of
distance between observed condition (comorbidity) and its average over the entire cohort. If the z-score of a condition is
positive in a state, we note that the condition is expressed in the state; conversely, if the z-score is negative, the condition is
suppressed in the state. To ensure that a diverse range of conditions is covered, a comprehensive set of comorbidity measures,
30 types in all, are included in the z-score analysis (please see Table 5 in the appendix for more detail for each type).
Z-score analysis on non-MODS states. As shown in Figure 5d, we find that none of the conditions are significantly
differentially expressed from the overall cohort in state A1. This is explained by the fact that state A1 represents a mild sepsis
state. A slightly increased differential expression of comorbidities is observed in state A3. In state A2, the z-score of weight
loss and alcohol abuse are significantly higher than other conditions, with values of 0.12 and 2.0, respectively. Other conditions
in this state with positive z-scores are paralysis and other neurological conditions, with values of 0.09 and 0.07, respectively. It
is known that alcohol abuse promotes intestinal inflammation and impairs the body’s ability to regulate inflammation193, 194.
Therefore, positive association between alcohol abuse and sepsis state A2 is expected.
Z-score analysis on MODS states. We observe strong association between MODS states and liver disease, as well as
coagulopathy. Damaged liver impairs the coagulation system195, 197. Therefore, we observe higher values of z-scores of liver
disease and coagulopathy in MODS states. The z-scores of liver disease in states A4, A5, and A6 are 0.79, 0.80, and 0.69,
respectively, and the z-scores of coagulopathy in states A4, A5, and A6 are 0.28, 0.23, and 0.35, respectively. Individuals with
poor kidney health manifest fluid and electrolyte imbalances. We observe positive z-scores of fluid and electrolyte imbalances
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in MODS states to varying extents. The z-score of fluid and electrolyte imbalances in states A4, A5, and A6 are 0.23, 0.17, and
0.06, respectively. Note that state A4 has the highest z-score for fluid and electrolyte imbalances among MODS states. In state
A4, a solid tumor is also observed as a significant comorbidity, with z-score of 0.15.
In the MODS states, there are other comorbidities that are associated with specific states. In state A5, the z-score associated
with depression is the second highest (0.45). Other conditions associated with depression including neurological disorders,
peptic ulcers, alcohol abuse, drug abuse, and obesity198–202, are associated with state A5. The z-scores of neurological disorders,
peptic ulcer, alcohol abuse, and obesity in state A5 are 0.16, 0.25, 0.23, and 0.15, respectively. Depression is also associated
with state A6. However, the associated disorders are different from those with state A5. Patients in state A6 exhibit association
with drug abuse and rheumatoid arthritis. The z-scores of depression, drug abuse, neurological disorders, and rheumatoid
arthritis in state A6 type are 0.28, 0.23, 0.29, and 0.13, respectively. Finally, valvular disease, pulmonary circulation, and
neurological disorders are expressed in state A6 and hypothesized to cause ischemic injury141, 196. Ischemia is a restriction in
blood supply to tissues, causing hypoxia. The existence of valvular disease and pulmonary circulation problems compromise
blood flow and carrying deoxygenated blood away from tissues, exacerbating pre-existing neurological disorders. The z-scores
of valvular disease and pulmonary circulation in state A5 are 0.12 and 0.17, respectively.
3 Discussion
We present a computational framework to identify disease states in sepsis from 16,546 distinct patients admitted to Beth Israel
Deaconess Medical Center between 2001 and 2012, collected from the MIMIC-III database51. We identified six sepsis states
(moderate, inflammatory, mild, and MODS 1, 2, 3) based on the measurement of 42 variables (demographic profiles, vital signs,
laboratory tests, mechanical ventilation status of the patients, and information on pre-existing clinical conditions) from these
sepsis patients.
Our framework identified the most discriminating attributes for each sepsis state and showed that each state manifests a
unique set of pathological responses, which correspond to different extents of organ dysfunction. These observations have two
significant implications: (i) in contrast to the SOFA metric, our method identifies a larger number of attributes to provide a
comprehensive view of sepsis symptoms, allowing for a more detailed diagnostic criterion; and (ii) it is possible to focus on a
smaller set of attributes to differentiate sepsis symptoms, potentially reducing the associated diagnostic time and associated
cost. Our identification of three distinct MODS states associated with a higher mortality rate, provides insight into advanced
management of sepsis in ICU environments.
We also analyzed the association of different demographics and comorbidity profiles with identified sepsis states. Our
results revealed that these sepsis states are composed of distinct populations with different demographics and comorbidity
profiles, some of which have been supported in prior results. We find that a higher percentage of patients in MODS states had
developed liver disease before the onset of sepsis, validating that patients with liver disease are more prone to developing severe
sepsis77. Patients with solid tumors may suffer from chronic advanced neoplasm and receive cancer chemotherapy, which
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weakens their immune system and disposes them to infective organisms, including multidrug-resistant organisms78, leading to
higher mortality if sepsis develops87–89. We find that solid tumors uniquely present in state A4 (highest mortality rate). Patients
with drug and alcohol abuse are found in state A5 (which manifests damage to the nervous system). A possible reason is that
patients with drug abuse are more likely to lack self-consciousness, suffer from malnutrition, and cause self-induced injury,
making them susceptible to injury and sepsis81, 85, 86. Furthermore, patients with alcohol abuse are more likely to develop liver
cirrhosis, leading to the development of sepsis with severe outcomes82–84. Patients with peptic ulcers can develop perforation
and peritonitis, which can lead to sepsis with severe outcomes. These patients are also over-represented in state A576. Patients
with Rheumatoid Arthritis are more likely to develop severe sepsis due to the use of cytokine antagonists, such as DMARD
(Disease Modifying Anti-Rheumatoid Drug) and NSAIDs (Non-Steroidal Anti-Inflammatory Drug). This masks symptoms of
severe infection, leading to the delay of diagnosis of sepsis80. We find that patients in state A6, in which liver and coagulation
systems are primarily affected, had rheumatoid arthritis as a pre-existing condition. Valvular heart disease patients develop
septic shock due to bacterial endocarditis, and mortality in infective endocarditis remains high79. These patients are also
over-represented in state A6 (third in mortality rate).
There are other results from our analyses that are new and merit further investigation. Patients with paralysis, weight loss,
or other neurological conditions are over-represented in state A2, and patients with AIDS are over-represented in state A3. We
note that our results imply correlations, not causation. For instance, a damaged liver impairs the coagulation system. Therefore,
patients with coagulopathy are found in states A4, A5, and A6. However, the development of coagulopathy might not be the
independent cause of severe sepsis or septic shock.
Although we used the most distinguishing attributes to analyze organ function, other attributes, including Arterial blood
gas (ABG), electrolytes, albumin, shock index, and hemoglobin, are also crucial in analyzing various aspects of the health
status of sepsis patients. We also investigated these variables and found that these variables provide significant insight into
patients’ health status in different sepsis states; many of which are consistent with current literature. However, there are a few
cases that are at odds with the current literature. We highlight a few cases here, and refer readers to the detailed description
in the supplementary results section: Analyses of other variables 5.1. Metabolic acidosis often occurs in sepsis patients with
organ failure72, 90, and metabolic alkalosis has been noticed in sepsis patients75. We also find that a higher percentage of
metabolic acidosis occurs in MODS types. However, we observe fewer cases of metabolic alkalosis in our cohort. We also
find that Arterial BE is a significant predictor of metabolic acidosis for sepsis patients. Hypocalcemia103, 104, measured by the
concentration of ionized calcium or serum calcium in the body, might be observed in critically ill patients, especially in those
with sepsis60, 105, and is reported to be associated with increased severity of illness and increased mortality60, 100, 101. We find
that low ionized calcium concentrations coincide with worse outcomes, while low serum calcium concentrations do not.
We note that magnesium sulfate is often administered to patients with severe sepsis and has observed beneficial effects65, 67, 95,
and that albumin, in addition to crystalloids, is often used for initial resuscitation and subsequent intravascular volume
replacement in patients with sepsis and septic shock47. However, the administration of magnesium sulfate is not discussed
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and implemented in current sepsis guidelines47, and the benefits of albumin for resuscitation for patients with sepsis remains
controversial49, 52, 114. Based on our identified sepsis states, future development of clinical trials may focus on analyzing the
role of magnesium and albumin administration in different sepsis states.
Finally, by comparing the SIRS scores, SOFA scores, and mortality rates across the states, we confirm that the SIRS metric
only identifies a subset of sepsis states47. Furthermore, our results show that the SOFA metric covers a broader spectrum of
disease states and is a more accurate predictor of mortality for sepsis patients116.
Overall, our framework provides new insight into understanding the complex states of sepsis. By analyzing the relationship
between the pre-existing comorbidities and sepsis states, one can anticipate the severity of outcomes and devise suitable
therapeutic strategies for individual patients. Future research could focus on designing clinical trials to further analyse the states
based on the pathophysiology and disease progression to establish more specific treatment guidelines for different sepsis states.
4 Methods
Patient cohort and data preprocessing.
We use the Medical Information Mart for Intensive Care version III (MIMIC-III) database to collect samples from five distinct
ICUs located in Boston, Massachusetts. The sample criteria for cohort selection are: (i) patients over 18 years of age at time of
ICU admission who did not withdraw from treatment, and whose mortality status was recorded; and (ii) patients who satisfied
sepsis-3 criteria1, i.e., SOFA score ≥ 2. The resulting cohort includes 16,546 distinct patients with 20,944 admissions in ICUs.
Outliers and errors were checked and the corrected and the k-nearest neighbor algorithm was used as an imputation method to
fill missing values204. Clinical variables associated with the patients are demographic, vital signs, lab values, severity measures
such as SIRS and SOFA scores, and other information relating to the use of a ventilator and number of comorbidities before
sepsis infection. We also track whether the patient survived for 48 hours, and extract history of 30 types of comorbidities118
before infection, as supplementary variables.
Archetypal analysis.213
Archetypal analysis views each point in a dataset as a mixture (convex combination) of “pure types”, or “archetypes”. The
convexity constraint here implies that in contrast to traditional clustering techniques that aim to identify “typical” representatives,
archetypal analysis aims to identify “extremal” points in the dataset. The archetypes are themselves mixtures (convex
combinations) of the points in the data set. Archetypes can be learned by minimizing the squared error in representing each
point as a mixture of archetypes. Specifically, let x1, . . . ,xn be the data points inRm. The problem is to find a set of archetypes
{z1, . . . ,zK} so that each archetype zk is a convex combination of the data points, i.e., ∑nj=1βk jx j, with the constraints of: (i)
βk j ≥ 0 ∀ j; and (ii) ∑nj=1βk j = 1 (convexity constraint), and that each data point xi can be best approximated by a convex
combination of the archetypes, i.e., ∑Kk=1αikzk, with the constraints: (i) αik ≥ 0 ∀i; and (ii) ∑pk=1αik = 1.
18/46
We can then define the following optimization problem:
min
{αik,βk j}
n
∑
i=1
∥∥∥∥∥xi− p∑k=1αik
n
∑
j=1
βk jx j
∥∥∥∥∥
2
, (1)
and the archetype problem is to find α’s and β ’s to minimize the objective 1 subject to the aforementioned constraints. This
problem can be solved using general-purpose constrained nonlinear least squares methods211, 212, the alternating minimizing
algorithm213, or the projected gradient procedure214. The learned archetypes (for K >1) form a convex hull of the data set such
that all of the points can be well-represented as a convex mixture of the archetypes. In our study, we treat patient measurements
as the point set and find the archetypes for our cohort. These archetypes represent the extreme states in sepsis, derived from our
cohort, and each patient can be viewed as a convex combination of the extreme sepsis states.
Comparing mean vectors from two populations129.
We use Two-sample Hotelling’s T2 tests to characterize significant differences between the mean vectors of two multivariate
distributions (in reality, datasets drawn from these distributions). Two-sample Hotelling’s T2 tests are sensitive to violations of
the assumption of equal variances and covariances131. Different approximation of the sample variance is needed when the
covariance matrices of the two populations are significantly different. We use Box’s M test for significant differences between
covariance matrices.
Testing homogeneity of covariance matrices : Box’s M Test130.
Consider a sample set {x11, . . . ,x1n1} inRm sampled from population Θ1 and a sample set {x21, . . . ,x2n2} inRm sampled from
population Θ2. Assuming that the sample sizes n1 and n2 are sufficiently large, Box’s M Test tests the null hypothesis that
the population covariance matrices are equal, i.e., H0 : Σ1 = Σ2. Let S1 and S2 be the sample covariance matrices from the
populations Θ1 and Θ2, where each S j is based on n j independent observations, we define the pool variance Spooled as follows:
Spooled =
1
n1 +n2−2 (n1−1)S1 +(n2−1)S2,
and the value of M is given by:
M = (n1 +n2−2) ln |Spooled |− ((n1−1) ln |S1|+(n2−1) ln |S2|) .
Then, M(1− c) has an approximate χ2d f -distribution, where:
c =
2m2 +3m−1
6(m+1)(n1 +n2−1)
(
1
n1−1 +
1
n2−1 −
2
n1 +n2−2
)
,
d f =
m(m+1)(n1 +n2−1)
2
.
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The null hypothesis H0 is rejected when M(1− c)> χ2d f (α) (or p-value < α) .
Testing homogeneity of mean vectors : Hotelling’s T-Squared test.
We test the equality of vector means from populations Θ1 and Θ2. The null hypothesis is that the population means are equal,
i.e., H0 : µ1 = µ2. If Box’s M test indicates that the two covariance matrices are not significantly different, we can assume
Σ1 = Σ2 and:
T 2 = (x¯1− x¯2)ᵀ
(
(
1
n1 +n2
)Spooled
)−1
(x¯1− x¯2).
If Box’s M test concludes that Σ1 6= Σ2,
T 2 = (x¯1− x¯2)ᵀ
(
1
n1
S1 +
1
n2
S2
)−1
(x¯1− x¯2)
In either case, T 2 approximates chi-square distribution with m degrees of freedom, i.e., χ2m. The null hypothesis is rejected
when T 2 > χ2m(α) (or p-value < α) .
Low-dimensional embeddings of dataset.
We use Uniform Manifold Approximation and Projection (UMAP)27 to compute a mapping from a dataset X = {x1, . . . ,xn} in
Rm to its corresponding lower-dimensional representation Y = {y1, . . . ,yn} inRd that preserves as much of the local and the
global structure from the original space. UMAP assumes that the dataset X is uniformly drawn from a Riemannian manifold M.
With this assumption, the goal is to reconstruct M and to find a mapping from M intoRd . To do so, UMAP first approximates
the manifold and finds a fuzzy simplicial set that captures all topological properties of the manifold M. Similarly, given a
current lower-dimensional representation in Y ′ of the data X inRm, it can also construct a fuzzy simplicial set from Y ′. Having
the two fuzzy simplicial sets, one constructed from X and the other constructed from Y ′, UMAP then measures how good Y ′ is
as a representation of X using cross-entropy C of two fuzzy sets:
C((A,µ),(A,υ)) = ∑
a∈A
(
µ(a) log
(
µ(a)
υ(a)
)
+(1−µ(a)) log
(
1−µ(a)
1−υ(a)
))
The above objective function can be minimized using first-order optimization methods132, 133 or second-order meth-
ods2, 46, 205, 209, 210.
Feature selection methods.3,28,30
Quality-index based approach.
Given a set S = {x1, . . . ,xN} of N points in Rm that is partitioned as PK = {C1, . . . ,CK}, where for each cluster pair Ci,C j
,1 ≤ i, j,≤ K and i 6= j, Ci⋂C j = Φ, define gk to be the mean values of the instances in cluster Ck, g be the average values
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over all the instances in S, the total inertia T = ∑Ni=1 d2(xi,g) measures the dispersion of the points in the set S, where
d2(xi,xi′) = ∑mj=1(xi j− xi′ j)2 is the squared Euclidean distance. According to Huygens-Steiner Theorem, the total inertia T
can be decomposed into inter-cluster inertia B and within-cluster inertia W :
T = B+W
=
K
∑
k=1
d2(gk,g)+
K
∑
k=1
I(Ck)
=
K
∑
k=1
d2(gk,g)+
K
∑
k=1
∑
i∈Ck
d2(xi,g)
Here, inter-cluster inertia B measures the separation between the clusters, I(Ck) is the inertia for cluster Ck, and the within-cluster
inertia W is the summation of the inertia of the clusters that measures the heterogeneity within the clusters.
Variable quality. The quality index is given by the ratio of the homogeneity value of each cluster and the corresponding
homogeneity value associated with the partition P0 = S. This can be interpreted as the gap between the null hypothesis, i.e.,
partition into one cluster, and partition into k clusters. We can use the quality index at each variable (in our case, patient feature)
j to find the importance of the features. Given a set of points S partitioned by PK , the null hypothesis is that the total inertia of
the system is Tj. Since the partition PK is given, the total inertia of the system is fixed at Tj and the optimal strategy of assigning
clusters is to select minimal within-cluster inertia, Wj. This leads to the following ratio as a measure of variable quality:
Q j(Pk) =
B j
Tj
= 1−Wj
Tj
,
Wj = ∑
i∈Ck
(xi j−gk j)2,
Tj =
N
∑
i=1
(xi j−g j)2.
Alternatively, since the partition PK is given, we can ignore the variability of within-cluster inertia in the variable quality
measure. That is, we only consider how each variable contributes to the total inter-cluster inertia:
Q′j(Pk) =
B j
∑pi=1 Bi
.
In our study, we use both Q j(PK) and Q′j(PK) variable quality measures for feature selection. We also include a third feature
selection criteria based on a variation test.
Variation test.
Given a partition PK = {C1, . . . ,CK} of a set of points S, we can regard the points in cluster Ci as being sampled from a distinct
multivariate probability distribution Θi. To find the j-th feature that can distinguish the clusters, there exist at least two pairs
of marginal distributions such that the difference of the mean value at the j-th feature sampled from the compared marginal
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distributions is larger than some threshold θ with probability 1− δ , where δ is sufficiently small. We set θ = σi j when
comparing clusters Ci and Cl (l 6= i) and collect the union of the variables from each case as the selected features. Although
this feature selection method treats each dimension independently, we find that the selected features are similar to those using
quality-index based approaches. See section supplementary 5.3 for a detailed comparison.
Co-occurrence analysis29.
Let A be a random variable that maps sepsis states a1, . . . ,aK to binary values that indicate the presence of an event in interest.
Let S be the sample set S = {(ai1,ylj1), . . . ,(aiN ,yljN)} of size N sampled from the joint probability distribution Pr(A,Y ). We can
characterize the information in S by its sufficient statistics ni j = |(ai,ylj)∈ S|, which measures the frequency of co-occurrence of
ai and y j . We partition S into subsets Si based on the output of the random variable A. The sample set Si represents an empirical
distribution n j|i over Y l , where n j|i = ni j/ni and ni is defined as the cardinality of Si. Here, n j|i measures the frequency of an
outcome of interest, conditioned on the presence of the sepsis state i.
Z-score analysis.
The event of interest may be universally present in all sepsis states. In this case, n j|i≈ n j|i′ for all (i, i′) pairs. Specifically, n j|i
is agnostic of the presence of the sepsis state i and n j|i is approximately equal to n j/|S| computed over the entire population.
We aim to assess whether the event of interest is uniquely expressed or suppressed in a certain sepsis state. We compute the
corresponding Z-score :
zi j =
wi j−µ
σ
,
where µ = n j/|S| is the mean value over the entire population, σ is its corresponding standard deviation, and wi j is the reference
point, i.e., n j|i. Here, zi j measures how far the the reference point wi j is from population mean for the sepsis state i. If zi j is
positive, wi j is expressed in sepsis state i, and vice versa.
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5 Supplementary Material
5.1 Analyses of other variables.
Arterial blood gas (ABG). ABG is a blood test that assesses the gas exchange and acid-base balance of the body. It is an
essential marker for critical patients admitted to ICUs. Arterial PH, PaO2, PaCO2, HCO3, and Arterial base excess are the main
components of ABG. The presence of acidosis (arterial PH less than 7.35) or alkalosis (arterial PH higher than 7.45) is assessed
by measuring arterial PH in the blood74. Combined with arterial pH and PaCO2, one can measure the existence of respiratory
acidosis or respiratory alkalosis in the body. Respiratory acidosis occurs when PaCO2 is higher than 45 mmHg, with an arterial
PH less than 7.35. Respiratory alkalosis occurs when PaCO2 is less than 35 mmHg, with an arterial PH higher than 7.45.
Combined with arterial PH and HCO3, one can measure the existence of metabolic acidosis or metabolic alkalosis. Metabolic
acidosis occurs when HCO3 is less than 22 mEq/L, with an arterial PH less than 7.35. Metabolic alkalosis occurs when HCO3
is higher than 28 mmHg, with an arterial PH higher than 7.45. Among four types of acid-base disorders (respiratory acidosis,
respiratory alkalosis, metabolic acidosis, and metabolic alkalosis ), metabolic acidosis is common in sepsis patients with organ
failure72, 90. Metabolic alkalosis has been noted in sepsis patients75. In our cohort, we find that the average values of arterial
PH and HCO3 in MODS states are lower than non-MODS states, indicating that a higher portion of patients with metabolic
acidosis is observed in MODS states. The average values of arterial PH for states A1 through A6 are 7.39, 7.40, 7.39, 7.35, 7.37,
and 7.36, respectively. The average values of HCO3 for states A1 through A6 are 24.68, 25.06, 24.47, 22.79, 23.08, and 21.93,
respectively. The percentage of patients with metabolic acidosis in states A1 through A6 are 8.7%, 6.6%, 6.7%, 22.8%, 16.4%,
and 20.5%, respectively. On the other hand, we observe fewer cases of metabolic alkalosis in our cohort. The percentage of
patients with metabolic alkalosis in states A1 through A6 are 4.5%, 6.2%, 3.9%, 4.7%, 2.6%, and 1.1%, respectively.
Arterial base excess (Arterial BE). Arterial BE reflects the metabolic component of the acid-base balance. Arterial BE
measures the amount of H+ required to return the blood PH to normal when PaCO2 is within the normal range, with the
normal range from -2 to +2. The base excess increases in metabolic alkalosis and decreases (or becomes negative) in metabolic
acidosis. Metabolic acidosis is common in sepsis patients with organ failure72, 90, and metabolic alkalosis can also occur in
sepsis patients75. In our study, we find that the average value of arterial BE in MODS states is negative, indicating an inclination
towards metabolic acidosis in MODS states. The average values of arterial BE for states A1 through A6 are 0.35, 0.80, 0.37,
-1.9, -1.94, and -2.5, respectively, and the percentage of patients with metabolic acidosis in states A1 through A6 are 8.7%,
6.6%, 6.7%, 22.8%, 16.4%, and 20.5%, respectively. Therefore, arterial BE is an important predictor of metabolic acidosis for
sepsis patients.
Albumin. Albumin is one of the essential proteins, with a normal range of 3.4 to 5.4 g/dl. Albumin is responsible for plasma
colloid osmotic pressure, acting as a major binding protein for endogenous and exogenous compounds (drugs), with antioxidant
and anti-inflammatory properties, and operates as a buffer to balance acid-base status of the body48. A lower albumin level
(Hypoalbuminemia) is often observed when: (i) patients have nutritional deficiencies206; (ii) patients develop chronic liver
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disease, advanced hepatic cirrhosis, or end-stage renal disease208; or (iii) an inflammation is present207. Albumin, in addition
to crystalloids, is often used for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis
and septic shock47. Although albumin administration is widely used in the management of sepsis, the benefit of the use of
albumin for resuscitation in this population remains controversial49, 52, 114– while several meta-analyses have shown that the
administration of albumin in ICU patients has beneficial effects on health outcomes55, 56, 113, 115, other studies have shown
contradictory results48, 57, 108. However, the results are less conclusive when the included studies have differing experimental
design and comparison groups. As a result, albumin administration is suggested with weak confidence47. In our study, we
find hypoalbuminemia in all sepsis states, and the albumin level in various sepsis states is not significantly different. Future
development of clinical trials may focus on comparing the effects of albumin administration on the health outcomes for different
sepsis states.
Hemoglobin (Hb). The normal range of hemoglobin for males and females is 13.5 to 17.5 grams per deciliter and 12.0 to 15.5
grams per deciliter, respectively. A lower hemoglobin level in the body indicates a low red blood cell (RBC) count (Anemia).
Anemia is common in sepsis due to inflammation, liver and renal impairment, and cancer109–112. RBC transfusion is strongly
recommended for patients with sepsis when hemoglobin concentration falls to less than 7.0 g/dL in adults in the absence of
extenuating circumstances, such as myocardial ischemia, severe hypoxemia, or acute hemorrhage47. We find that the average
Hb values in all sepsis states are lower than the normal range, with A2 (Inflammation state) having the lowest Hb values. The
average Hb values for states A1 through A6 are 10.30, 9.49, 10.49, 10.42, 10.90, and 10.75, respectively.
Shock index (SI). Shock index (SI) is a bedside assessment defined as heart rate (HR) divided by systolic blood pressure
(SysBP), with a normal range of 0.5 to 0.7 in healthy adults106. SI is suggested as a measure in the triage and management of
critically ill patients. Its use is also suggested as a predictor of clinical outcomes, such as the serum lactate level in the body,
the risk of mortality, and other markers of morbidity58, 59, 102, 106, 107. However, a retrospective database review shows that SI
does not correlate with the mortality rate in emergency room patients44. Our results support this claim. We find that SI is not
highly associated with worse outcomes. While the MODS states display higher SI than A1 and A3 states, A2 (Inflammation
state) displays the highest SI, which is the state associated with lower SOFA score and mortality rate. The average SI values for
states A1 through A6 are 0.75, 0.81, 0.72, 0.77, 0.79, and 0.77, respectively. Furthermore, SI is not an independent predictor of
hyperlactatemia (serum lactate ≥ 4.0 mmol/L): while A2 state manifests the highest average SI, it displays the lowest arterial
lactate. The average arterial lactate levels for states A1 through A6 are 2.04, 1.88, 2.10, 5.50, 3.95, and 4.58.
Ionized calcium. In health, serum ionized calcium concentration is maintained between approximately 1.16 and 1.32 mmol/L.
Ionized hypocalcemia (ionized calcium levels < 1.16 mmol/L) are common in critically ill patients with sepsis, cardiac failure,
pulmonary failure renal failure, post-surgery or burns60, 100, 101. Recent studies show that low ionized calcium concentrations
coincide with increased severity of illness and increased mortality60, 100, 101. We find that ionized hypocalcemia occurs in all
sepsis states, and the average ionized calcium concentration in MODS states is lower than non-MODS states. The average
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ionized calcium concentration for states A1 through A6 are 1.13, 1.13, 1.14, 1.08, 1.09, and 1.09, respectively.
Calcium. The normal range of total serum calcium concentration is 8.8 mg/dL to 10.7 mg/dL. Hypocalcemia103, 104, defined
as serum calcium concentration less than 8.8 mg/dL or serum ionized calcium concentration less than 4.7 mg/dL, is common in
critically ill patients, especially in those with sepsis60, 105. We find that hypocalcemia occurs in all sepsis states. However, low
serum calcium concentrations do not coincide with the increased severity of illness and increased mortality. The serum calcium
concentrations for states A1 through A6 are 8.31, 8.39, 8.38, 8.50, 8.13, and 8.20, respectively.
Magnesium. Magnesium is a vital element involved in various physiological processes61, 98, 99 and an essential cofactor in
more than 300 enzymes97, with a normal range of 1.5 to 2.5 mEq/L in healthy adults. Hypomagnesemia (serum Mg levels < 1.5
mEq/L) can occur in critically ill patients, including sepsis patients, and is associated with prolonged ICU stay, increased need
for mechanical ventilation, and increased mortality62–64, 96. In our study, we find that, in the average case, serum magnesium
levels in all sepsis states are within the normal range. The average values of serum magnesium levels for states A1 through
A6 are 2.06, 2.07, 2.02, 2.10, 2.04, and 2.29, respectively. We note that recent studies have shown that the administration
of magnesium sulfate increases lactate clearance in critically ill patients with severe sepsis95, improve cerebral perfusion in
patients with sepsis-associated encephalopathy (SAE)67, and may be used to open up small vessels, to reduce organ failure for
patients with severe sepsis and septic shock65. Future development of clinical trials may focus on comparing the effects of the
administration of magnesium sulfate on the health outcomes for different sepsis states.
Chloride. Chloride is an essential anion of the extracellular fluid, representing two-thirds of all negative charges in plasma
and accounting for nearly one-third of plasma tonicity66. Normal Serum chloride concentrations range from 96 to 106. mEq/L.
Abnormal chloride levels in the blood (hypo- and hyperchloremia) are observed in critically ill patients68. However, evidence
on the effects of hypo- and hyperchloremia on the clinical outcomes, such as length of stay and mortality rate, are sparse69, 70.
A recent study shows that hyperchloremia is not significantly related to an increased mortality rate, and hypochloremia is
associated with increased mortality in patients with severe sepsis or septic shock91. Our results are consistent with these
findings: we observe a higher percentage of hypochloremia in MODS groups, which are the groups associated with a higher
mortality rate. We also observe that hyperchloremia does not directly correlate with MODS groups. The percentage of patients
with hypochloremia for states A1 through A6 are 7%, 7%, 5%, 15%, 12%, and 10%, respectively, and the percentage of patients
hyperchloremia for states A1 through A6 are 39%, 27%, 36%, 30%, 35%, and 35%, respectively. Future development of
clinical trials may focus on comparing the effects of chloride levels on clinical outcomes in different sepsis states.
Sodium. The normal sodium level in the blood is 135 to 145 mEq/L. Hypernatremia (serum sodium concentration > 145
mEq/L )93 is an uncommon but important electrolyte abnormality in ICU patients. Hypernatremia also occurs in sepsis
patients, but only a few studies71, 92, 94 have investigated the effect of serum sodium levels on the clinical outcomes in sepsis
patients. Studies have shown that patients admitted with hypernatremia are significantly more likely to have sepsis71 and
that hypernatremia is strongly associated with worse outcomes in sepsis94. However, we notice that sepsis patients with
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hypernatremia only constitutes 7.3% in the cohort and that although we find that state A4 (the state with highest mortality rate)
constitutes the highest portion of patients with hypernatremia, state A5 (the state with second-highest mortality rate) has a
lower portion of patients with hypernatremia than the cohort. The percentage of patients with hypernatremia for states A1
through A6 are 7.3%, 8.1%, 4.1%, 10.8%, 4.5%, and 8.8%, respectively.
Potassium. Potassium is one of the electrolytes mostly present in intracellular fluid42. The normal value of serum potassium
is 3.5 to 5.0 mEq/L. Potassium homeostasis is important for negative resting membrane potential, neuromuscular, and cardiac
excitability. Abnormal potassium has adverse effects on the heart: both hypo and hyperkalemia cause cardiac arrhythmia.
Hypokalaemia also causes muscle paralysis, including respiratory muscles and GIT. Potassium abnormality can occur in
critically ill patients in ICU due to organ derangement and some medications, and is associated with an increased complication
rate and mortality risk4, 5, 43. Our study found that the average potassium levels do not vary across sepsis states and are within
the normal range in our cohort. The average potassium concentration for states A1 through A6 are 4.08, 4.22, 4.14, 4.31, 4.06,
and 4.34, respectively.
5.2 SOFA and SIRS scores.
Systemic Inflammatory Response Syndrome (SIRS). Sepsis was first defined as a systemic inflammatory response syn-
drome (SIRS)117. SIRS is the clinical presentation of the host response to inflammation. It manifests in four symptoms,
temperature ≥ 38 degree Celsius or ≤ 36 degree Celsius, respiratory rate ≥ 20 breaths/minute or PaCO2 < 32 mm of Hg,
heart rate > 90 beats/minute, white blood count >12000/mm3 or < 4000/mm3 or bands > 10%. Two or more symptoms of
SIRS indicate a SIRS positive case120. However, it was argued that SIRS is not an adequate measure, since a sepsis-related
symptom may be observed without infection. Due to its non-specific issue, the diagnostic metric of sepsis was first replaced by
sepsis-2126, and finally changed to Sequential Organ Failure Assessment Score (SOFA).
Sequential Organ Failure Assessment1 (SOFA) Score. SOFA measures the functionality of six organ systems – respiratory,
coagulation, cardiovascular, neurological, liver, and renal, shown in Table 2, each of which is measured by PaO2/FiO2 ratio,
platelet count, mean arterial pressure (MAP), Glasgow coma score (GCS), bilirubin, and creatinine or urine output, respectively.
Each system is assigned a score from 0 to 4. The worst condition represents the highest score. The range of the SOFA score is
0-24. It has been shown that the SOFA score is a good predictor of mortality in intensive care units121–123.
5.3 Performance analysis for the feature selection methods.
We compare the top 15 features selected by (i)Q j(Pk) method measuring the ratio of inter-cluster inertia at the i-th feature Bi to
the total inertia at the i-th feature Ti, (ii) Q′j(Pk) method measuring the ratio of the between-cluster inertia at i-th feature Bi
to the total between-cluster inertia ∑pi=1 Bi, (iii) and the feature that has a lower probability of overlapping between clusters.
The selected features are shown in Table 3. We observe that the first five features selected by Q j(Pk) and Q′j(Pk) are identical
– SGOT, SGPT, PaO2/FiO2, PaO2, and Platelet Count, in the same order, except for PaO2 and Platelets. For the rest of the
features selected by Q j(Pk) and Q′j(Pk), PT, WBC Count, Arterial Lactate, Age, and HR were selected by both Q j(Pk) and
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Table 2: Sequential Organ Failure Assessment Score
SOFA Respiratory Cardiovascular Nervous Hepatic Renal Coagulation
score PaO2/ FiO2ratio
Mean Arterial
Pressure/
vasopressors
Glasgow
coma
score
Bilirubin,
mg/dl
Creatinine,
mg/dl
(or urine
output)
Platelets
( × 103/mm3)
0 ≥ 400 ≥ 70 mm/Hg 15 < 1.2 < 1.2 ≥ 150
1 < 400 < 70 mm/Hg 13 - 14 1.2 - 1.9 1.2 - 1.9 < 150
2 < 300
dopamine ≤ 5 or dobutamine
(any dose) 10 - 12 2 - 5.9 2.0 - 3.4 < 100
3 < 200
dopamine > 5, epinephrine ≤ 0.1
or norepinephrine ≤ 0.1 6 - 9 6 - 11.9
3.5 - 4.9 (or <
500 ml/d) < 50
4 < 100
dopamine > 15, epinephrine >
0.1 or norepinephrine > 0.1 < 6 > 12
> 5.0 (or < 200
ml/d) < 20
Table 3: List of the top 15 features selected by Q j(Pk) and Q′j(Pk) methods, and the features selected by variation test method.
Method \Rank 1 2 3 4 5
Q j(Pk) SGOT SGPT PaO2/FiO2 PaO2 Platelets
Q′j(Pk) SGOT SGPT PaO2/FiO2 Platelets PaO2
Variation Test SGOT SGPT PaO2/FiO2 Platelets PaO2
Method \Rank 6 7 8 9 10
Q j(Pk) Arterial lactate FiO2 WBC Count INR Mechvent
Q′j(Pk) Glucose Age PT HR PTT
Variation Test Arterial lactate FiO2 PT INR Mechvent
Method \Rank 11 12 13 14 15
Q j(Pk) PT GCS Age HR Comorbidity Count
Q′j(Pk) WBC Count Weight BUN Arterial lactate DiaBP
Variation Test WBC Count GCS Creatinine N/A N/A
Q′j(Pk). Among the 10 features mentioned above, 8 are selected by the variation test as well. We present a Venn diagram for the
inclusion-exclusion comparison between Q j(Pk), Q′j(Pk), and the variation test in Figure 3. We observe that the three methods
are largely consistent in selecting representative features from the clusters.
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5.4 Additional Figures and Tables.5.4 A ditional Figures and Tables.
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Figure 6: Percentile value (y-axis) of each variable (x-axis) in an archetype, as compared to the overall cohort.
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Table 4: Statistics of the clinical variables for each sepsis state.
Demographic Type or Unit A1 Mean (std) A2 Mean (std) A3 Mean (std) A4 Mean (std) A5 Mean (std) A6 Mean (std)
Age years 64.663 (16.602) 56.5665 (18.7243) 64.8518 (17.2279) 62.7714 (16.2069) 51.574 (21.7017) 54.2832(22.129)
Gender binary 0.4395 (0.4963) 0.3514 (0.4775) 0.4778 (0.4996) 0.4078 (0.4917) 0.4739 (0.5003) 0.5852(0.5003)
Vitals
HR bpm 87.1709 (16.7968) 95.5663 (18.356) 84.9405 (16.3634) 88.7297 (19.2053) 90.9378 (19.2497) 89.2824(19.3743)
SysBP mmHg 119.8967 (20.3539) 121.4193 (19.5506) 120.7683 (19.9297) 119.37 (22.4043) 119.8301 (21.3859) 119.5795(20.9424)
MeanBP mmHg 78.1903 (13.4654) 80.0547 (14.2412) 78.8656 (13.9104) 77.2155 (15.2942) 81.1584 (15.2533) 78.1294(13.3615)
DiaBP mmHg 57.0701 (13.293) 59.554 (13.8632) 58.3062 (13.826) 58.0745 (15.1096) 60.4603 (15.3068) 56.9948(13.8887)
Temp Celsius 36.9064 (1.7824) 37.3685 (11.044) 36.7529 (1.4197) 36.6214 (3.0829) 36.9874 (0.9774) 36.8557(0.941)
RR bpm 20.2032 (5.1781) 21.885 (6.2891) 19.5003 (4.7369) 20.6665 (6.0007) 21.0097 (5.601) 20.8984(5.1881)
Lab Values
GCS N/A 12.562 (3.4477) 12.2389 (3.5298) 13.9572 (2.3921) 10.6749 (4.7609) 11.2034 (4.4437) 11.7657 (4.0345)
SpO2 percent 96.9089 (2.642) 97.1831 (2.4756) 97.077 (2.1706) 95.9839 (4.7988) 96.231 (4.3131) 95.9966 (5.9411)
FiO2 Fraction 0.463 (0.183) 0.4735 (0.1903) 0.2841 (0.0749) 0.5193 (0.2122) 0.4761 (0.217) 0.4661 (0.2163)
Potassium mEq/L 4.0755 (0.5561) 4.2223 (0.5966) 4.1442 (0.6301) 4.3133 (0.7767) 4.0643 (0.6654) 4.3403 (0.6969)
Sodium mEq/L 138.6984 (4.8889) 138.3988 (5.0606) 138.1455 (4.4043) 138.9389 (5.4767) 138.5481 (4.5309) 138.5624 (5.5003)
Chloride mEq/L 104.7454 (6.2452) 103.4621 (5.855) 104.4564 (5.7471) 102.4878 (7.5266) 103.4479 (7.3862) 103.7934 (7.0719)
Glucose mg/dl 139.0001 (51.0059) 133.4703 (44.9989) 137.6523 (55.9765) 150.8865 (77.058) 138.8868 (63.89) 120.5447 (38.2647)
BUN mg/dl 29.3086 (22.6237) 24.962 (19.8349) 26.684 (20.6605) 33.6255 (20.5769) 26.2646 (17.4777) 29.3539 (18.5723)
Creatinine mg/dl 1.4887 (2.1789) 1.0243 (0.8691) 1.499 (1.6191) 2.0458 (1.5894) 1.994 (1.8473) 2.0084 (1.9972)
Magnesium mg/dl 2.0551 (0.3503) 2.0673 (0.3121) 2.0169 (0.3344) 2.1042 (0.3923) 2.0373 (0.4165) 2.2905 (1.0883)
Calcium mg/dl 8.3114 (0.7968) 8.3944 (0.7641) 8.3835 (0.7654) 8.5005 (1.1839) 8.1258 (0.8741) 8.202 (0.8551)
Ionised Ca mmol/L 1.1317 (0.1223) 1.1315 (0.0942) 1.1394 (0.1016) 1.0837 (0.1306) 1.0718 (0.11) 1.0935 (0.1253)
CO2 mEq/L 25.8455 (5.6656) 26.4052 (5.4564) 24.8079 (4.6421) 24.1683 (6.8329) 24.6976 (6.4869) 23.2444 (6.0989)
SGOT u/L 121.1987 (319.2254) 115.2526 (328.7376) 97.1299 (281.488) 6.56 × 103 (1.49 × 103) 2.01 × 103 (1.76 × 103) 7.66 × 103 (1.43 × 103)
SGPT u/L 104.709 (292.993) 103.3734 (292.2103) 81.6814 (254.6595) 3.02 × 103 (1.20 × 103) 6.39 × 103 (1.52 × 103) 6.69 × 103 (1.15 × 103)
Total Bilirubin mg/dL 2.4088 (5.1579) 1.9281 (4.4836) 1.9465 (4.2194) 5.3717 (5.7693) 3.3705 (2.1968) 4.5556 (6.3519)
Albumin g/dL 2.9994 (0.6756) 2.8733 (0.6736) 3.195 (0.6969) 2.9661 (0.619) 3.0209 (0.685) 2.9535 (0.5675)
Hb g/dL 10.3025 (1.733) 9.488 (1.5127) 10.4938 (1.8691) 10.42 (1.7506) 10.8988 (1.9639) 10.7478 (1.9296)
WBC × 109 /L 12.227 (8.2151) 20.698 (15.4674) 10.9535 (6.3327) 13.1239 (7.9441) 11.2392 (4.9433) 13.0102 (6.8857)
Platelets × 109 /L 223.7886 (126.0426) 905.5808 (158.9635) 229.6721 (130.2459) 185.0943 (121.6149) 189.9349 (104.536) 194.6217 (127.3292)
aPTT s 37.7794 (19.3023) 37.5194 (18.7424) 37.839 (20.2669) 44.1421 (23.6432) 41.6113 (23.9075) 43.1402 (21.2096)
PT s 16.1654 (6.6965) 15.9141 (5.0994) 15.8759 (6.3263) 20.6772 (10.9054) 21.9298 (11.9564) 25.9364 (19.0131)
INR N/A 1.5081 (0.8252) 1.4644 (0.6116) 1.4806 (0.7861) 2.0823 (1.324) 2.4955 (2.0079) 2.9554 (2.8588)
Arterial PH N/A 7.3905 (0.0741) 7.3987 (0.081) 7.3945 (0.0713) 7.3531 (0.1014) 7.3738 (0.095) 7.3579 (0.0957)
PaO2 mmHg 120.8273 (64.1414) 121.7747 (60.9402) 381.0231 (79.3787) 126.9464 (72.8629 120.977 (70.0857) 117.9201 (50.4301)
PaCO2 mmHg 41.9729 (10.832) 41.7772 (10.6985) 40.872 (8.6858) 41.2665 (11.7813) 39.2051 (10.6536) 39.862 (11.6424)
Arterial BE mEq/L 0.3591 (5.0242) 0.7962 (5.2063) 0.367 (3.9529) -1.919 (6.6414) -1.9408 (5.8841) -2.4647 (6.6472)
Arterial lactate mmol/L 2.0365 (1.6021) 1.877 (1.4591) 2.0957 (1.5675) 5.498 (5.3563) 3.9508 (3.9727) 4.581 (4.5874)
HCO3 mEq/L 24.6844 (5.0834 25.0584 (4.9991) 24.4738 (4.7358) 22.7896 (6.1283) 23.0842 (5.6634) 21.9257 (5.7679)
Shock Index bpm/mmHg 0.7483 (0.1962) 0.8057 (0.1997) 0.7223 (0.185) 0.7707 (0.2386) 0.7874 (0.2371) 0.7713 (0.2254)
PaO2/FiO2 mmHg 292.9807 (172.172) 294.5925 (179.6651) 1.38 × 103 (300.0487) 285.0333 (205.488) 318.1304 (272.0889) 301.8456 (164.0181)
Others
Weight kg 83.2915 (24.6464) 81.9459 (24.443) 79.2817(22.7953) 85.1836(28.6976) 89.298 (35.9261) 82.3125 (24.2238)
Mechvent binary 0.373 (0.4836) 0.3314 (0.4708) 0.0918(0.2888) 0.5627(0.4963) 0.5037 (0.5009) 0.4148 (0.4934)
Comorbidity Count Integer 4.0159 (2.1709) 3.0843 (2.0466) 3.6575(2.0539) 4.6206(2.2385) 4.291 (2.0927) 4.2841 (1.9404)
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Table 5: Definitions of Comorbidities.
Comorbidity ICD-9-CM Codes
DRG Screen: Case Does Not Have
the Following Disorders (DRG):
Congestive heart failure
398.91, 402.11, 402.91, 404.11, 404.13, 404.91,
404.93,428.0–428.9
Cardiaca
Cardiac arrhythmias
426.10, 426.11, 426.13, 426.2–426.53,
426.6–426.89, 427.0, 427.2, 427.31,
427.60,427.9, 785.0, V45.0, V53.3
Cardiaca
Valvular disease
093.20–093.24, 394.0–397.1, 424.0–424.91,
746.3–746.6,V42.2,V43.3
Cardiaca
Pulmonary circulation disorders 416.0–416.9, 417.9 Cardiaca or COPD
Peripheral vascular disorders
440.0–440.9, 441.2, 441.4, 441.7, 441.9,
443.1–443.9, 447.1,557.1,557.9, V43.4
Peripheral vascular (130–131)
Hypertension (combined)
Hypertension, uncomplicated
Hypertension, complicated
401.1, 401.9
402.10, 402.90, 404.10, 404.90, 405.11, 405.19,
405.91, 405.99
Hypertension (134)
Hypertension (134) or cardiaca or renala
Paralysis 342.0–342.12, 342.9–344.9 Cerebrovascular (5, 14–17)
Other neurological disorders
331.9, 332.0, 333.4,333.5,334.0–335.9,340,
341.1–341.9,345.00–345.11,
345.40–345.51, 345.80-345.91, 348.1,
348.3, 780.3, 784.3
Nervous system (1–35)
Chronic pulmonary disease
490–492.8, 493.00–493.91, 494, 495.0–505,
506.4
COPD (88) or asthma (96–88)
Diabetes, uncomplicatedb 250.00–250.33 Diabetes (294–295)
Diabetes, complicatedb 250.40–250.73, 250.90-250.93 Diabetes (294–295)
Hypothyroidism 243–244.2, 244.8, 244.9 Thyroin (290) or endocrine (300–301)
Renal failure
403.11, 403.91, 404.12, 404.92, 585, 586,
V42.0,V45.1,V56.0,V56.8
Kidney transplant (302) or renal failure/dialysis (316–317)
Liver disease
070.32, 070.33, 070.54, 456.0, 456.1, 456.20,
456.21 571.0, 571.2, 571.3,
571.40–571.49, 571.5, 571.6, 571.8,
Livera
Peptic ulcer disease excluding
bleeding
531.70, 531.90, 532.70, 532.90, 533.70,
533.90,534.70,534.90, V12.71
GI hemorrhage or ulcer (174–178)
AIDSb 042–044.9 HIV (488–490)
Lymphoma
200.00–202.38, 202.50–203.01,203.8–203.81,
238.6, 273.3,V10.71,V10.72,V10.79
Leukemia/lymphomaa
Metastatic cancerb 196.0–199.1 Cancera
Solid tumor without
metastasisb
140.0–172.9,174.0–175.9,179–195.8,
V10.00–V10.9
Cancera
Rheumatoid arthritis/collagen
vascular diseases
701.0, 710.0–710.9, 714.0–714.9,
720.0–720.9, 725
Connective tissue (240–241)
Coagulopathy 2860–2869, 287.1, 287.3–287.5 Coagulation (397)
Obesity 278.0 Obesity procedure (288) or nutrition/metabolic (296–298)
Weight loss 260–263.9 Nutrition/metabolic (296–298)
Fluid and electrolyte disorders 276.0–276.9 Nutrition/metabolic (296–298)
Blood loss anemia 2800 Anemia (395–396)
Deficiency anemias 280.1–281.9, 285.9 Anemia (395–396)
Alcohol abuse
291.1, 291.2, 291.5, 291.8, 291.9,
303.90-303.93,305.00–305.03, V113
Alcohol or drug (433–437)
Drug abuse
292.0, 292.82–292.89,292.9,304.00–304.93,
305.20-305.93
Alcohol or drug (433–437)
Psychoses 295.00–298.9, 299.10–299.11 Psychose (430)
Depression 300.4, 301.12, 309.0, 309.1, 311 Depression (426)
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; DRG, diagnosis-related group; COPD, chronic obstructive pulmonary
disease; GI, gastrointestinal; AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus.
a Definitions of DRG groups: Cardiac: DRGs 103–108, 110–112, 115–118, 120-127, 129, 132–133, 135-143; Renal: DRGs 302-305, 315–333; Liver: DRGs
199-202, 205-208; Leukemia/lymphoma: DRGs 400-414, 473, 492; Cancer: DRGs 10, 11, 64, 82, 172, 173, 199, 203, 239, 257–260, 274, 275, 303, 318, 319,
338, 344, 346, 347, 354, 355, 357, 363, 366, 367, 406–414.
b A hierarchy was established between the following pairs of comorbidities: If both uncomplicated diabetes and complicated diabetes are present, count only
complicated diabetes. If both solid tumor without metastasis and metastatic cancer are present, count only metastatic cancer.
∗This table is adopted from A., Steiner et al.118.
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